论文部分内容阅读
目的:观察福莫特罗联合布地奈德治疗慢性支气管哮喘的疗效和安全性。方法:80例慢性支气管哮喘患者随机均分为对照组和试验组。对照组患者给予糖皮质激素、抗菌药物或多索茶碱等常规治疗;试验组患者在对照组治疗基础上给予福莫特罗粉吸入剂1吸+布地奈德粉吸入剂1吸,均为雾化吸入,每日1~2次。两组患者疗程均为2周。观察两组患者的临床疗效,治疗前后白细胞介素(IL)-17、IL-33、1秒用力呼气容积(FEV1)/用力肺活量(FVC)比值、呼气峰值流速(PEF),日间、夜间症状评分及不良反应发生情况。结果:试验组患者总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者IL-17、IL-33和日间、夜间症状评分均显著低于同组治疗前,且试验组低于对照组,FEV1/FVC、PEF均显著高于同组治疗前,且试验组高于对照组,差异均有统计学意义(P<0.05或P<0.01)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗基础上,福莫特罗联合布地奈德治疗慢性支气管哮喘的疗效和安全性均较好。
Objective: To observe the efficacy and safety of formoterol and budesonide in the treatment of chronic bronchial asthma. Methods: Eighty patients with chronic bronchial asthma were randomly divided into control group and experimental group. Control group patients were given glucocorticoids, antibiotics or doxofylline and other conventional treatment; patients in the experimental group were given formoterol powder inhalation on the basis of the control group 1 inhalation + budesonide powder inhaler 1 suction, were Inhalation inhalation, 1 or 2 times a day. Two groups of patients were treated for 2 weeks. The clinical efficacy, IL-17, IL-33, FEV1 / FVC, peak expiratory flow (PEF), daytime , Nighttime symptom score and adverse reactions. Results: The total effective rate of the experimental group was significantly higher than that of the control group, the difference was statistically significant (P <0.05). After treatment, IL-17, IL-33 and daytime and nighttime symptom scores in both groups were significantly lower than those in the same group before treatment, and the FEV1 / FVC and PEF in the experimental group were significantly lower than those in the control group , And the experimental group than the control group, the difference was statistically significant (P <0.05 or P <0.01). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion: The efficacy and safety of formoterol combined with budesonide in the treatment of chronic bronchial asthma are better than conventional treatment.